|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR2500104924 |
|
最近更新日期: Date of Last Refreshed on: |
2025-06-25 15:01:01 |
|
注册时间: Date of Registration: |
2025-06-25 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
瑞马唑仑复合舒芬太尼对老年患者支气管镜术后认知功能的影响 |
|
Public title: |
The effect of remimazolam combined with sufentanil on postoperative cognitive function in elderly patients after bronchoscopy |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
瑞马唑仑复合舒芬太尼对老年患者支气管镜术后认知功能的影响临床研究方案 |
|
Scientific title: |
The effect of remimazolam combined with sufentanil on postoperative cognitive function in elderly patients after bronchoscopy |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
郭焱 |
研究负责人: |
郭焱 |
|
Applicant: |
GuoYan |
Study leader: |
GuoYan |
|
申请注册联系人电话: Applicant telephone: |
+86 135 9327 2620 |
研究负责人电话:
Study leader's |
+86 135 9327 2620 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
guoyanfuwai2015@163.com |
研究负责人电子邮件: Study leader's E-mail: |
guoyanfuwai2015@163.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
山西省长治市潞州区解放东街161号长治医学院 |
研究负责人通讯地址: |
山西省长治市潞州区解放东街161号长治医学院 |
|
Applicant address: |
No. 161, Jiefang East Street, Luzhou District, Changzhi, Shangxi, China |
Study leader's address: |
No. 161, Jiefang East Street, Luzhou District, Changzhi, Shangxi, China |
|
申请注册联系人邮政编码: Applicant postcode: |
046000 |
研究负责人邮政编码: Study leader's postcode: |
046000 |
|
申请人所在单位: |
长治医学院附属和济医院 |
||
|
Applicant's institution: |
Heji Hospital Affiliated to Changzhi Medical College |
||
|
研究负责人所在单位: |
长治医学院附属和济医院 |
||
|
Affiliation of the Leader: |
Heji Hospital Affiliated to Changzhi Medical College |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
K25-032 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
长治医学院附属和济医院伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Heji Hospital Affiliated to Changzhi Medical College |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2025-04-28 00:00:00 | ||
|
伦理委员会联系人: |
李俊岩 |
||
|
Contact Name of the ethic committee: |
Li Junyan |
||
|
伦理委员会联系地址: |
山西省长治市潞州区解放东街161号 |
||
|
Contact Address of the ethic committee: |
No. 161, Jiefang East Street, Luzhou District, Changzhi, Shangxi, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 180 3559 0866 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
hjkjk2095026@163.com |
|
研究实施负责(组长)单位: |
山西省长治市长治医学院附属和济医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Heji Hospital Affiliated to Changzhi Medical College |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
山西省长治市潞州区解放东街161号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 161, Jiefang East Street, Luzhou District, Changzhi, Shangxi, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
自筹 |
||||||||||||||||||||||
|
Source(s) of funding: |
Funds raised by oneself |
||||||||||||||||||||||
|
研究疾病: |
术后认知功能障碍 |
||||||||||||||||||||||
|
Target disease: |
Postoperative cognitive dysfunction |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
干预性研究 |
||||||||||||||||||||||
|
Study type: |
Interventional study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
非随机对照试验 |
||||||||||||||||||||||
|
Study design: |
Non randomized control |
||||||||||||||||||||||
|
研究目的: |
评估与比较瑞马唑仑与丙泊酚对老年人支气管镜术后认知功能的影响。 |
||||||||||||||||||||||
|
Objectives of Study: |
Evaluation and comparison of the effects of remimazolam and propofol on cognitive function in elderly patients after bronchoscopy surgery. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
年龄≥60岁,男性或女性;美国麻醉医师协会分级I-III;患者及家属同意参与研究。 |
||||||||||||||||||||||
|
Inclusion criteria |
Age >= 60 years old, male or female; American Society of Anesthesiologists classification I-III; patients and their families agree to participate in the study. |
||||||||||||||||||||||
|
排除标准: |
拒绝参加研究或计划接受支气管镜治疗的个体,严重心脏、脑、肺、肝、肾或代谢疾病史,既往从异常手术麻醉中恢复史,ECG记录显示HR < 50次/ min,2周内未治愈的急性呼吸道炎症史,神经肌肉或精神疾病患者,食管反流病患者,怀疑滥用麻醉性镇痛药或镇静剂的患者;预计可能患有或以前患有呼吸道困难,已知对脂肪乳、苯二氮卓类药物和阿片类药物过敏,在三个月内参加过其他药物试验,或无法有效沟通或不合作。 |
||||||||||||||||||||||
|
Exclusion criteria: |
Refusal to participate in the study or individuals who planned to undergo bronchoscopy therapy,a history of severe cardiac, cerebral, pulmonary,hepatic, renal, or metabolic diseases, a history of previous recovery from abnormal surgical anesthesia, ECG recording indicating HR < 50 beats/ min, a history of acute respiratory inflammation that had not been cured within 2 weeks, patients with neuromuscular or psychiatric disorders, individuals with esophageal reflux disease, those suspected of narcotic analgesics or sedatives abuse; predicted to have possible or had previous difficult airways, known to be allergic to fat emulsions, benzodiazepines and opioids, had participated in other drug trials within three months, or were unable to communicate effectively or were uncooperative. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2025-07-01 00:00:00至 To 2026-07-01 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2025-07-02 00:00:00 至 To 2026-07-01 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
None |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
无 |
|
Blinding: |
None |
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
是Yes |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
我组项目原始数据,将于2027 年 5 月 20 日在长治医学院官网(网址:https://www.czmc.com/ )正式公布 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
The original data of our project will be officially released on the official website of Changzhi Medical College (website address: https://www.czmc.com/) on May 20, 2027. |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
本研究CRF严格遵循既定方案,在受试者签署知情同意书后,通过专业人员使用标准化工具和流程采集数据。从基线信息录入、干预过程记录到结局指标测量,每个环节均设置双人核对机制,确保数据真实准确。原始数于长据统一存储长治医学院科研数据中心的加密服务器,配备冗余备份系统,确保数据安全不丢失。同时,采用分级访问权限管理,仅授权人员可进行数据操作。 |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
This study strictly followed the established protocol. After the subjects signed the informed consent form, data were collected by professionals using standardized tools and procedures. From the entry of baseline information, the recording of the intervention process to the measurement of outcome indicators, a double-checking mechanism was set up at each stage to ensure the authenticity and accuracy of the data. The original data were uniformly stored in the encrypted server of the Research Data Center of Changzhi Medical College and equipped with a redundant backup system to ensure the data security and prevent loss. At the same time, a hierarchical access permission management system was adopted, and only authorized personnel were allowed to perform data operations. |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
暂未确定/Not yet |